Nucleic acid tests are performed in order to detect the presence of viral DNAs or RNAs in blood samples of patients. Three major processes involved in NAT are sample pooling and nucleic acid (NA) extraction, target NA amplification and target amplicon NA detection.Major NAT technologies include polymerase chain reaction (PCR), strand displacement amplification (SDA), ligase chain reaction (LCR), transcription-mediated amplification (TMA) and nucleic acid sequence based amplification (NASBA). Based on its major applications, NAT market can be classified into five major segments namely infectious diseases, genetic diseases, cancer, forensic testing and paternity testing.
Report Overview @ https://www.transparencymarketresearch.com/nucleic-acid-testing.html
Major growth drivers for the NAT market will include increasing prevalence of infectious diseases, cancer and genetic diseases, growing demand for technological advancements in testing methods, increasing end user acceptance and favorable regulatory mechanisms worldwide. It was estimated that approximately one billion people suffered from various infectious diseases worldwide in 2012, which is one of the major segments of the NAT market, thus will affect this markets growth in future. Growing demand for new and improved testing methods that utilizes new reagent systems and automated amplification systems in wide range of applications will also provide this market a larger share in the coming future.
Geographically, North America dominated the global NAT market with the largest share in terms of revenue, followed by the European region. Asia-Pacific is expected to be the fastest growing market in the coming future because in most of its countries, the NAT market is currently at nascent stage or underpenetrated. This region is likely to evolve under the influence of increasing awareness regarding the testing methods and continuously improving economic condition. The major players operating in the NAT market are Abbott Laboratories, Inc., Becton, Dickinson and Company, Beckman Coulter, Inc.,Bio-Rad Laboratories, Inc., Illumina, Inc., Siemens Healthcare, Gen-Probe, Inc., bioMérieux SA, Novartis AG, F. Hoffmann-La Roche Ltd., Sequenom, Inc.and Tecan Group Ltd.